-
艾媒咨询|2021年9月中国医疗健康行业投融资数据分析报告
人口老龄化,人均GDP、人均收入的提升,同时也带来了人们健康需求的增长。近年来,医疗健康产业创新不断涌现,并发展成为最活跃的行业之一,相关细分赛道也维持着较高的增长,收获了资本市场的大量关注。
艾媒咨询通过艾媒数据中心(data.iimedia.cn)查询并发布《2021年9月中国医疗健康行业投融资数据分析简报》,助力投资人与创业者用户即时了解市场趋势,获取关键投资决策所需的数据,把握投资逻辑和最新产业机会。(《艾媒咨询|2021年9月中国医疗健康行业投融资数据分析报告》完整高清PDF版共21页,可点击文章底部报告下载按钮进行报告下载)
The aging of population and the increase of per capita GDP and per capita income have also brought about the growth of people's health demand. In recent years, the innovation of medical and health industry has been emerging and developed into one of the most active industries. The relevant segments have also maintained high growth and gained a lot of attention from the capital market.
Iimedia inquires and publishes the analysis briefing on investment and financing data of “China's medical and health industry in September 2021 through iimedia data center (data. Iimedia. cn), so as to help investors and entrepreneurs understand the market trend in real time, obtain the data required for key investment decisions, and grasp the investment logic and the latest industrial opportunities.(“iiMedia Report |Analysis report on investment and financing data of China's medical and health industry in September 2021”full version has 21 pages in total, please click the Browse HD Report button on the right side of the article to browse the report) -
艾媒咨询|2021全球及中国大健康产业运行大数据及决策分析报告
本报告研究涉及企业/品牌/案例:阿里健康,联合丽格,恒瑞医药,白云山,平安好医生,111集团,新氧,药明巨诺,盘龙药业,先导药业,好大夫在线,优健康,春雨医生,丁香医生,微医
受到人口老龄化、居民患病比例增加等因素影响,国家医疗费用支出不断增加,属于刚性需求;同时,随着人们对健康标准的不断提高以及互联网医疗技术的发展,大健康产业会在相当长的时期内持续保持增长态势。数据显示,2020年中国的大健康产业营收规模超过7万亿元,预计2021年将达8万亿元,增幅达8.1%。其中,得益于大健康产业发展以及疫情期间医药需求增长,生物制药、医疗器械两大细分领域表现良好,成为2020年中国投资热度较高的新经济行业,投资项目金额分别为919亿元和273亿元。
Affected by the aging population and the increasing proportion of residents, the national medical expenditure is increasing, which belongs to the rigid demand; At the same time, with the continuous improvement of people's health standards and the development of internet medical technology, the big health industry will continue to grow for a long time. According to the data, the revenue of China's big health industry will exceed 7 trillion yuan in 2020, and it is expected to reach 8 trillion yuan in 2021, an increase of 8.1%. Among them, thanks to the development of big health industry and the growth of pharmaceutical demand during the epidemic period, biopharmaceuticals and medical devices have performed well, becoming China's new economy industry with high investment enthusiasm in 2020, with investment projects of 91.9 billion yuan and 27.3 billion yuan respectively. -
艾媒咨询|2020年第三季度中国中药材行业数据监测季度报告
本报告研究涉及企业/品牌/案例:同仁堂、香雪制药、白云山。
数据显示,2020年第三季度,中药材价格指数迎来上涨周期。艾媒咨询分析师认为,受动物类等少数品种拉动影响,预计2020年10-11月中药材指数会持续走高,但是在12月维稳。据调查,绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营,采取减少压货炒作等经营方式。因而,预计中药材市场在2020年末旺季会有一波行情的走高,但随着旺季结束,明年年初的价格会重新回落,随着疫情的常态化,中药材市场行情预期会呈周期性波动的态势。
Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation. -
艾媒报告|2020年全球消毒杀毒产品市场分析及发展趋势报告
本报告研究涉及企业/品牌/案例:老肯医疗,新华医疗,威莱,三友化工;
其他提及企业/品牌:滴露,威露士,蓝月亮,洗得宝,威猛先生,如辉,巨光,海氏海诺,威王,净安,优露清,利尔康,安洁,威洁士,欧洁,仁和,泰和科技,京汉股份,比亚迪,仁瑞生物科技,盘龙药业,东北制药等。
2020年4月28日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020年全球消毒杀毒产品市场分析及发展趋势报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对全球消毒杀毒产品进行全面分析,并且通过对三友化工、威莱集团(威尔士)、新华医疗和老肯医疗的典型企业案例分析,特别结合新冠疫情影响下消毒杀毒用品的用户调研,判断2020-2021年全球消毒杀毒行业发展趋势。随着经济环境和人民生活水平不断改善,国家对于医疗卫生更加重视,卫生投入不断增加,医疗机构数量显著增长,居民的卫生健康意识也持续提高,从需求端拉动消毒产品行业发展。特别在新冠疫情影响下,消毒杀毒产品的需求量骤升,其中小包装的消杀产品需求量特别大,短期消杀用品存在供需结构矛盾。
In 2020, the national medical institutions and other public places need large-scale, long-term, high-frequency disinfection, in addition, the public awareness of home disinfection has also given birth to a huge demand for disinfection products. According to iiMedia Research, the new crown outbreak in 2020 has had an impact on the purchase of disinfection products by 84% of consumers, with the market value of disinfection products expected to reach 38.26 billion yuan for the full year. -
艾媒报告|2020H1后疫时代全球呼吸机等医疗器械产品监测及企业案例报告
本报告研究涉及企业/品牌/案例:美敦力,GE医疗,迈瑞医疗,万孚生物,鱼跃医疗,乐普医疗,九安医疗;其他提及企业/品牌:冠昊生物,华海药业,金域医学,卫宁健康,新和成,健帆生物,费森尤斯医疗,嘉德诺,丹纳赫,史赛克,依视路陆逊梯卡,创业慧康,康恩贝,华北制药,通用电气,西门子,飞利浦,3M,绿盾,霍尼韦尔,保为康POWECOM,CM朝美,UVEX优唯斯,南丁,云南白药,维康WECAN,振德医疗,迪卡侬,锐步,速尔,爱康,KEEP,李宁,亿健,舒华,WALKINGPAD,英派斯,SKG,本博,倍轻松,南极人,凯仕乐,佳仁,茗振,小熊,璐瑶,攀高
2020年4月21日,全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020H1后疫时代全球呼吸机等医疗器械产品监测及企业案例报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据,对全球范围内的医疗器械产品进行全面分析,并且报告聚焦于疫情问题下的呼吸机、额温枪等医疗器械,具体针对美敦力、GE医疗、迈瑞医疗、万孚生物、鱼跃医疗和乐普医疗等典型案例分析,对2020-2021年医疗器械行业发展进行趋势预判。特别在全球新冠肺炎疫情的严峻情势下,呼吸机、额温枪等医疗器械需求猛增,飞利浦、美敦力等西方医疗器械企业快速提高产量,以支持抗疫工作的迫切需求;同时,中国呼吸机等医疗器械企业的海外业务量有明显增长。艾媒咨询分析师认为,全球疫情势必带动医疗器械行业发展,但中国企业应当在保证自身产品质量的基础上抓住机遇,实现业务出海。
According to the data, the global medical device market has continued to increase in size since 2016, and the global medical device market is expected to reach USD 477.4 billion in 2020. Especially under the influence of the New Crown epidemic, the global demand for medical equipment such as ventilators and oxygen concentrators has increased dramatically. Overseas orders for Chinese medical device companies have skyrocketed. Within a certain period, the concept stocks of ventilator in the A-share market have risen. -
艾媒报告 |2019中国基因测序产业研究和商业应用分析报告
本报告研究涉及企业/品牌/案例:Thermo Fisher(美),Illuminate(美),(瑞士),Stem cells(加),R&D(瑞士),华大基因,贝瑞基因,金城检验,美吉生物,恒创基因,基研生物,谱元科技,景杰生物,燃石生物,基迪奥生物,谷和信息,圣庭生物,天昊生物,诺禾致源,百迈克生物,思博奥科,赛莱拉,赛贝、北昊干细胞,达安基因,燃石医学、泛生子基因、世和基因,臻和生物,鹍远基因,23魔方,瀚海基因,百奥赛图,克睿基因,药明明码,裕策生物
随着基因测序的技术推进,基因测序开始应用于生物、侦查、无创产前检测和肿瘤治疗等场景中。技术的市场化应用吸引了全球资本方关注,iiMedia Research(艾媒咨询)数据显示,2018年全球医疗健康领域资本市场中,生物技术领域获得309件投资案共138亿元美元,领跑所有细分领域。中国生物技术科研研发实力厚积薄发,特别是科创板推动了基因测序市场的进一步升温,越来越多的生物创业公司在创业初期已获得高额融资。目前,中国已经基本形成了完整的上中下游产业链,但除了华大基因、贝瑞基因等少数头部企业,中国基因测序企业多数分布于产业链中下游,并且开始出现产品同质化等问题。艾媒咨询分析师认为,第二代测序技术的普及以及第三代测序技术的加紧研发将使得基因测序作为一个更加普遍的技术手段应用到不同场景之中,但目前仍然存在监管体系不够完善、道德伦理风险等问题。企业方面应当专注研究核心技术专利,通过人才储备和差异化竞争获得市场优势;行业和相关部门应当尽快完善行业规范管理体系,推动产业健康发展。
With the advancement of gene sequencing technology, gene sequencing began to be used in biological, detection, noninvasive prenatal testing and tumor treatment and other scenarios. The market-oriented application of technology has attracted global capital attention, with iiMedia Research leading all segments of the world in 309 investments in the global healthcare capital markets in 2018, with 309 investments, according to iiMedia Research. China's biotechnology research and development strength thick and thin hair, especially the science and technology board to promote the gene sequencing market further heating up, more and more bio-startup companies in the early stage of the start-up has been high financing. At present, China has basically formed a complete upstream and downstream industrial chain, but in addition to Huada gene, Berry gene and a few other head enterprises, Most of China's gene sequencing enterprises are distributed in the middle and lower reaches of the industrial chain, and began to appear product homogenization and other issues. Ai media consulting analysts believe that the popularity of second-generation sequencing technology and the third generation of sequencing technology will make gene sequencing as a more common technical means to apply to different scenarios, but there are still problems such as inadequate regulatory system, ethical risks. Enterprises should focus on researching core technology patents and gain market advantages through talent pool and differentiated competition, and industries and related departments should improve the industry standard management system as soon as possible to promote the healthy development of the industry. -
艾媒报告 |2019中国人造肉产业研究与消费者行为调查报告
本报告研究涉及企业/品牌/案例:Beyond Meat,Impossible Foods,杜邦,Ripple Foods,Bolthouse Farms,Roquette,Field Roast,Gardein,Mosa Meat,Modern Meadow,Finless Foods,烟台双塔食品,深圳齐善食品,宁波素莲素食,江苏鸿旭食品,万达财富,来伊份,登海种业,大北农,新开疆,京粮控股,四环生物,九芝堂,ST天宝,友好集团,爱普股份,丰乐种业,北大荒,天士力,中源协和,大康农业,东宝生物,融捷健康,华宝股份,戴维医疗,千红制药,金健米业,圣济堂,济民制药,哈高科,国际医学,维维股份,海欣食品,复星医药,苏常柴A,瑞茂通
人造肉主要包括植物肉、培育肉和混合肉三类。随着全球肉类短缺危机、健康与环保的消费风潮、食品创新推动等因素带动人造肉产业发展,资本市场开始关注人造肉产业,例如,Beyond Meat上市股市表现良好,Impossible Foods已完成超过6.875亿美元的多轮融资。中国的人造肉市场也开始发展,艾媒商情舆情数据监测系统显示,广东网民最关注人造肉议题。在资本和舆论的带动下,A股市场人造肉版块的活跃,同时,各类人造肉的上游产业链如大豆、豌豆蛋白、胎牛血清等开始共同发展。iiMedia Research(艾媒咨询),36%的中国消费者并不了解人造肉,同时低于四成消费者愿意尝试人造肉。艾媒咨询分析师认为,人造肉要真正市场化普及仍需克服成本、技术、消费者心理因素等多重障碍。
Artificial meat mainly includes three types of plant meat, cultivated meat and mixed meat. With the global meat shortage crisis, the consumption trend of health and environmental protection, and the promotion of food innovation, the capital market has begun to focus on the artificial meat industry. For example, Beyond Meat listed stocks performed well, and Impossible Foods has completed more than 687.5 million. Multiple rounds of financing for the dollar. China's artificial meat market has also begun to develop, and the iiMedia Research business data analysis system shows that Guangdong netizens are most concerned about artificial meat issues. Driven by capital and public opinion, the artificial meat section of the A-share market is active. At the same time, the upstream industrial chains of various types of artificial meat, such as soybean, pea protein and fetal bovine serum, have begun to develop together. iiMedia Research, 36% of Chinese consumers do not know about artificial meat, and less than 40% of consumers are willing to try artificial meat. Ai Media Consulting analysts believe that the real marketization of artificial meat still needs to overcome multiple obstacles such as cost, technology and consumer psychological factors. -
艾媒报告 |2019中国3·15消费者权益调查报告网民健康篇
近几年,中国居民人均医疗保健消费支出均保持10%以上的增长水平。2018年居民人均医疗保健消费支出达1685元,同比增长16.1%。中国国内经济增长及居民消费水平的提高刺激了居民医疗消费需求的不断增长。大健康产业蓬勃发展的浪潮中,乱象横生、问题众多。市场监管的不规范、营销骗局层出不穷、假药频出等,不仅骗取群众血汗钱,更是严重危害人民生命健康。艾媒大数据舆情监控系统数据显示,医美、保健品及生物制药成为大健康产业问题重灾区。在健康产业下衍生的各种产品,消费者尤其关注产品的安全性、个人隐私的保护及价格等问题。作为与老百姓生命和健康安全紧密相关的领域,大健康行业在用药安全、销售诚信、售后服务等任何一个环节都容不得半点瑕疵。同时,也对构建更加完善的监管制度、更严格的惩戒体系、更畅通的信息发布机制提出更高的要求。
According to iiMedia Research data, the current demand of logistics enterprises for smart logistics mainly includes logistics data, logistics cloud and logistics equipment. In 2018, the smart logistics market will exceed 400 billion yuan. It is expected that by 2025, the smart logistics market will exceed trillion yuan. iiMedia Consulting analysts believe that with the development of IoT, AI and other technologies, as well as the higher requirements for logistics in new retail, intelligent manufacturing and other fields, the scale of intelligent logistics market will continue to expand. At the same time, the development of new retail, the upgrading of consumer consumption and the increase of user experience expectations have contributed to the gradual expansion of demand in the real-time distribution industry. It is expected that the number of users in China's distribution industry will reach 421 million in 2019, and there is still potential for continued growth. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
- 1
- 2
- 3
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告